Hematology

The Leukemia & Lymphoma Society (LLS) is known for its assistance to patients, but did you know that this organization also offers many resources for clinicians as well?

The Food and Drug Administration approved filgrastim-aafi (Nivestym), a biosimilar to filgrastim (Neupogen), for all eligible indications of the original product.

This hike marks the fifth continent to be visited by a Moving Mountains for Multiple Myeloma team.

The FDA has approved the oral IDH1 inhibitor ivosidenib (Tibsovo) for the treatment of adult patients with relapsed/refractory IDH1-mutant acute myeloid leukemia (AML).

Two randomized phase III clinical trials are designed to determine whether guadecitabine (SGI-110), a potent second-generation hypomethylating agent, could answer unmet medical needs for patients with certain types of blood cancer.

CURE Media Group

Adding nelarabine to escalating-dose methotrexate increased the 4-year disease-free survival rate to 91% in pediatric and young adult patients with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma, according to results from the phase III AALL0434 trial.

Standardized and focused education for patients receiving CAR T-cell therapy and their caregivers should be part of discharge procedures.

The FDA granted a priority review to a new drug application for glasdegib, an investigational oral smoothened inhibitor, for the treatment of adult patients with previously untreated acute myeloid leukemia in combination with low-dose cytarabine, a type of chemotherapy.

The phase IIb UNITY-NHL clinical trial (NCT02793583) aims to determine whether the novel drug umbralisib (TGR-1202) could be used as monotherapy or in combination with other drugs to treat patients with relapsed/refractory non-Hodgkin lymphoma (NHL).

The FDA has granted a priority review to a supplemental new drug application for ibrutinib (Imbruvica) for use in combination with rituximab (Rituxan) as a treatment option across all lines of therapy for patients with Waldenström macroglobulinemia, a type of non-Hodgkin lymphoma (NHL).

CE lesson worth 1 contact hour that is intended to advanced practice nurses, registered nurses, and other healthcare professionals who care for patients with cancer.

Selinexor (KPT-330), a promising drug that retards cell malignancy by blocking the transport of tumor-suppressor proteins out of the cell nucleus, is under investigation as combination therapy in heavily pretreated patients with relapsed/refractory multiple myeloma.

The MMRF was honored for the 15th year for outstanding stewardship of donors’ funds.

Researchers at the National Institutes of Health are exploring whether CAR T-cell therapy can enhance the effectiveness of treatment with hematopoietic cell transplant (HCT) among patients with relapsed/refractory acute lymphoblastic leukemia (ALL).

Patients with relapsed/refractory heavily pretreated multiple myeloma could live for an extra progression-free year with the use of the anti-BCMA CAR T-cell therapy bb2121.

The FDA has granted an accelerated approval to pembrolizumab (Keytruda) for the treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma (PMBCL), or those who have relapsed after 2 or more prior lines of therapy.

Phyllis McKiernan, MSN, APN, OCN, Blood & Marrow Transplant Program, John Theurer Cancer Center explains factors that go into choosing an iron chelation therapy for a patient with myelodisplastic syndrome (MDS) experiencing transfusion-related iron overload.

Based on results from the phase III MURANO trial, the FDA has granted a regular approval to venetoclax (Venclexta) in combination with rituximab for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, following at least 1 prior therapy.

A promising CD19-directed chimeric antigen (CAR) T-cell therapy, Lisocabtagene maraleucel (JCAR017; liso-cel), may result in durable remissions among patients with high-risk diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma.

Patients with relapsed/refractory heavily pretreated multiple myeloma could live for an extra progression-free year with the use of the anti-BCMA CAR T-cell therapy bb2121.

The FDA approved sargramostim (Leukine) for the treatment of adult and pediatric with hematopoietic subsyndrome of acute radiation syndrome (H-ARS).

Immuno-Oncology (IO) and novel agents targeting the microenvironment were the focus of the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).

The FDA has granted breakthrough therapy designation to the kinase inhibitor crizotinib (Xalkori) for two indications.

Oncology nurses play an important role in educating patients with chronic lymphocytic leukemia (CLL) about the adverse effects (AEs) associated with ibrutinib (Imbruvica) treatment.

When given before a stem cell transplant, busulfan plus melphalan, improved progression-free survival in patients with myeloma, but came with some extra adverse events.

A multidisciplinary team approach may help in seeing optimal patient outcomes following the administration of a powerful drug combination for patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Patient-reported outcomes allowed oncology nurses to better support patients’ needs.

The FDA has approved the monoclonal antibody daratumumab (Darzalex), in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) for the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

The FDA has approved the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel (Kymriah) for use in adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.